Loss of PRMT7 reprograms glycine metabolism to selectively eradicate leukemia stem cells in CML
the present invention also provides a method for treating an individual suffering from pancreatic cancer comprising the steps: pro-angiogenic regulators selected from the group consisting of VEGF, MMP-9, MMP- 2, TNF-a, IGF- 1, CXCR4, TGF- , EGFR, IL- , IL-6, bFGF, PDGF-BB, IL-8, Angiogenin, IL- l a, and Leptin, and/or detecting abnormally low levels of an RAS/RAF/MEK/ERK also known as MAP-Kinase (MAPK) Pathway, or ERK 1/ 2 Pathway MAPK MAP-Kinase ERK 1/ 2 Pathway cross-talk between PI3K/AKT/mTOR and RAS/RAF/MEK/ERK EGFR Epidermal Growth Factor Receptor IGF- 1 Insulin Growth Factor- 1 IAP family inhibitors of apoptosis IAP family inhibitors of apoptosis clAP l e.g., clAP l , cIAP2, XIAP, NAIP, ML-IAP, ILP2, Livin, Apollon and Survivin NF-kappaB NFKB Group V Enzymatic or Endocrine Abnormalities composition comprising at least one compound selected from the group of compounds corresponding to the pathway activation detected in (a) and (b) according to the following Table 9, said compound being administered in an amount effective to alter said abnormal or undesirable pathway activation toward normal, that is, toward a level of activity in an individual not exhibiting pancreatic cancer: the list of Table 8 includes typical daily doses for each compound
La inclusin de las sustancias activas como sibutramina y sildenafilo en cantidad suficiente para restaurar, corregir o modificar una funcin fisiolgica ejerciendo una accin farmacolgica puede producir reacciones adversas de diversa gravedad
They hypothesized that cysteine deprivation impairs the ETC activity and Krebs cycle, leading to hyperpolarization of the IMM followed by lipid peroxidation [230]
